BioArctic: Biologics License Application for lecanemab designated for Priority Review by China National Medical Products Administration
STOCKHOLM, Feb. 28, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for lecanemab (brand name
Source: finanznachrichten.de